Avanir Pharmaceuticals, Inc. (AVNR) was a big mover last session, as the company saw its shares rise more than 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 23.23% over the past one month time frame.
None of the estimates for this med-drugs stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Avanir Pharmaceuticals has a Zacks Rank #2 (Buy), while its Earnings ESP is 0.00%.
Investors interested in the sector may also consider stocks like Endocyte, Inc. (ECYT), Hyperion Therapeutics, Inc. (HPTX) and Lannett Company, Inc. (LCI). All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment